Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
for Advanced Malignant Solid Neoplasm
Drug: Retifanlimab
1 location in Portland
Sponsor: OHSU Knight Cancer Institute
Sex: All·Age: 18+
Code: NCT06320405·Phase 1, Phase 2·Recruiting·Listed Mar 2024